- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02721979
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
A Phase 2 Study of Apalutamide in Active Surveillance Patients
Study Overview
Status
Conditions
Detailed Description
OUTLINE:
Patients receive apalutamide orally (PO) once daily (QD) for 90 days in the absence of disease progression or unacceptable toxicity.
After completion of the study treatment, patients are followed up at 180, 365, 545, and 730 days; and at years 3, 4 and 5 by medical record review.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Have signed an informed consent document
- Be willing/able to adhere to the prohibitions and restrictions specified in this protocol
- Written authorization for use and release of health and research study information has been obtained
- Life expectancy >= 10 years (as determined by the treating physician)
- Eastern Cooperative Oncology Group (ECOG) performance status =< 1
- Histologically confirmed adenocarcinoma of the prostate as documented by a minimum 12 core prostate biopsy completed within 1-year of enrollment (note: most recent prostate biopsy must have demonstrated prostatic adenocarcinoma)
Favorable risk prostate cancer as defined by:
Very low-risk:
- Clinical stage T1c disease
- PSA density (PSAD) < 0.15 ng/mL
- Gleason score 6
- =< 2 core biopsies with =< 50% involvement of any biopsy core with cancer, or unilateral disease =< 2 core biopsies with any percentage involvement OR
Low risk:
- Clinical stage =< T2a
- PSA < 15 ng/mL
- Gleason score 6 OR
Low-intermediate risk:
- Clinical stage T1c
- PSA < 15 ng/ml
- Gleason 3+4 present in =< 50% of one core/site as detected by systematic biopsy or MRI/transrectal ultrasound (TRUS) fusion guided biopsy
- Gleason 6 disease in all other cores / sites
- Willing and qualified for active surveillance at Johns Hopkins or the University of Washington
- Serum testosterone >= 150 ng/dL
- Able to swallow the study drugs whole as a tablet
- Hemoglobin >= 9.0 g/dL, (at screening), independent of transfusion and/or growth factors within 3 months prior to registration
- Platelet count >= 100,000 x 10^9/uL (at screening) independent of transfusion and/or growth factors within 3 months prior to registration
- Serum albumin >= 3.0 g/dL (at screening)
- Glomerular filtration rate (GFR) >= 45 mL/min (at screening)
- Serum potassium >= 3.5 mmol/L (at screening)
- Serum total bilirubin =< 1.5 x upper limit of normal (ULN) (at screening) (note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 × ULN (at screening)
- Medications known to lower the seizure threshold must be discontinued or substituted at least 4 weeks prior to study entry
- Agrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
Exclusion Criteria:
- Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)
- Prior use of ARN-509 (apalutamide)
- Have known allergies, hypersensitivity, or intolerance to ARN-509 (apalutamide) or its excipients
Prior or ongoing systemic therapy for prostate cancer including, but not limited to:
- Hormonal therapy (e.g. leuprolide, goserelin, triptorelin)
- Cytochrome P450 (CYP)-17 inhibitors (e.g. abiraterone, ketoconazole)
- Antiandrogens (e.g. bicalutamide, nilutamide)
- Second generation antiandrogens (e.g. enzalutamide)
- Immunotherapy (e.g. sipuleucel-T, ipilimumab)
- Chemotherapy (e.g. docetaxel, cabazitaxel)
- Have any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study or prevent the subject from meeting or performing study requirements
History of any of the following:
- Seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to registration, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
- Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to registration
- Any condition that in the opinion of the investigator, would preclude participation in this study
Current evidence of any of the following:
- Uncontrolled hypertension
- Gastrointestinal disorder affecting absorption
- Active infection (e.g. human immunodeficiency virus [HIV] or viral hepatitis) or other medical condition that would make prednisone/prednisolone (corticosteroid) use contraindicated
- Any condition that in the opinion of the investigator, would preclude participation in this study
- The use of drugs known to lower the seizure threshold, including: atypical antipsychotics (e.g. clozapine, olanzapine, risperidone, ziprasidone), bupropion, lithium, meperidine, pethidine, phenothiazine antipsychotics (e.g. chlorpromazine, mesoridazine, thioridazine), and tricyclic antidepressants (e.g. amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine)
The use of strong CYP3A4 inhibitors, including: itraconazole, clarithromycin, erythromycin, diltiazem, verapamil, delavirdine, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole, grapefruit juice (or grapefruits)
- Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for enrollment if they can safely stop said medication; a two week or 5 half-lives, whichever is longer, washout will be required prior to enrolling on study; subject may not resume medication while receiving apalutamide
Strong CYP3A4 inducers, including: phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, efavirenz, tipranavir, St. John's wort
**Note: If a patient is on a strong CYP3A4 inhibitor, they can be reconsidered for enrollment if they can safely stop said medication; a two week or 5 half-lives, whichever is longer, washout will be required prior to enrolling on study; subject may not resume medication while receiving apalutamide
- Any psychological, familial, sociological, or geographical condition that could potentially interfere with compliance with the study protocol and follow-up schedule
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (apalutamide)
Patients receive apalutamide PO QD for 90 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Ancillary studies
Other Names:
Ancillary studies
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Negative (i.e. no Residual Carcinoma) Site Directed and Systematic Prostate Biopsy Rate
Time Frame: At 90 days
|
Negative rate will be presented as the percent of subjects with a negative repeat biopsy, and will be calculated as: (number of patients with a negative biopsy following 90-days of apalutamide) / (total number of patients enrolled on the study) x 100.
A 1-sample chi-square test will be used to compare the proportion with a negative repeat biopsy to the null hypothesis value of 20% (above).
The 95% confidence interval will be computed.
|
At 90 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Patients Exiting Active Surveillance for Any Reason
Time Frame: At 2 years
|
Percentage of patients exiting active surveillance for any reason will be computed along with its 95% confidence interval.
|
At 2 years
|
Prostate-specific Antigen Progression Free Survival as Defined by the Prostate Cancer Working Group 2 Criteria
Time Frame: At 2 years
|
Prostate-specific antigen progression free survival will be estimated using Kaplan-Meier methods and 95% confidence interval will be estimated using Greenwood's formula.
|
At 2 years
|
Change in Radiographic Disappearance of Magnetic Resonance Imaging Detectable Prostate Cancer
Time Frame: Baseline to up to 90 days
|
This calculates the percentage of participants with radiographic disappearance of magnetic resonance imaging detectable prostate cancer.
This is only in patients with a baseline nodule that is Prostate Imaging Reporting and Data System 3 or more and > 5 mm.
|
Baseline to up to 90 days
|
Percentage of Patients Exiting Active Surveillance Due to Pathologic Reclassification
Time Frame: At 2 years
|
The percentage of patients who exited active surveillance due to pathologic reclassification (e.g.
increasing tumor volume or gleason score) will be computed along with its 95% confidence interval.
|
At 2 years
|
Percent of Men Undergoing Local Treatment
Time Frame: At 2 years
|
Computed along with its 95% confidence interval.
|
At 2 years
|
Local Treatment Free Survival
Time Frame: Up to 730 days
|
Median treatment free survival will be estimated using Kaplan-Meier methods and 95% confidence interval will be calculated
|
Up to 730 days
|
Prostate-specific Antigen Progression Rate
Time Frame: At 2 years
|
Prostate-specific antigen progression rate is the proportion of patients that had PSA progression following treatment.
PSA progression is as a confirmed rising prostate-specific antigen >= 2 ng/mL, with subsequent PSA values obtained at least one week apart.
|
At 2 years
|
Change in Quality of Life: FACT-P Assessment
Time Frame: Baseline compared to 730 days
|
As assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) surveys.
Functional Assessment of Cancer Therapy-Prostate is a validated quality of life survey specific for patients with prostate cancer.
The total FACT-P score ranges from 0 to 156, with higher scores indicating better quality of life.
The change in FACT-P score between baseline and day 730 is reported.
|
Baseline compared to 730 days
|
Change in Quality of Life: SF-36 Physical Functioning
Time Frame: Baseline compared to 730 days
|
As assessed using the Short Form-36 (SF-36) survey physical functioning subscale.
Short Form-36 is a validated quality of life survey.
This is a generic survey to assess an individual's overall well-being, and is not specific to one disease.
The SF-36 physical functioning subscale score ranges from 0 to 100, with higher scores indicating better quality of life.
The change in SF-36 energy/fatigue subscale score between baseline and day 730 is reported.
|
Baseline compared to 730 days
|
Change in Quality of Life: SF-36 Energy/Fatigue
Time Frame: Baseline compared to 730 days
|
As assessed using the Short Form-36 (SF-36) survey energy/fatigue subscale.
Short Form-36 is a validated quality of life survey.
This is a generic survey to assess an individual's overall well-being, and is not specific to one disease.
The SF-36 energy/fatigue subscale score ranges from 0 to 100, with higher scores indicating better quality of life.
The change in SF-36 energy/fatigue subscale score between baseline and day 730 is reported.
|
Baseline compared to 730 days
|
Change in Quality of Life: SF-36 Emotional Well Being
Time Frame: Baseline compared to 730 days
|
As assessed using the Short Form-36 (SF-36) survey emotional well being subscale.
Short Form-36 is a validated quality of life survey.
This is a generic survey to assess an individual's overall well-being, and is not specific to one disease.
The SF-36 emotional well being subscale score ranges from 0 to 100, with higher scores indicating better quality of life.
The change in SF-36 emotional well being subscale score between baseline and day 730 is reported.
|
Baseline compared to 730 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 9582 (OTHER: Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (U.S. NIH Grant/Contract)
- NCI-2016-00221 (REGISTRY: CTRP (Clinical Trial Reporting Program))
- RG1716037 (OTHER: Fred Hutch/University of Washington Cancer Consortium)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Adenocarcinoma
-
Case Comprehensive Cancer CenterTerminatedAdenocarcinoma of Prostate | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Puerto Rico
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)CompletedStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States
-
Dana-Farber Cancer InstituteCompletedProstate Cancer | Adenocarcinoma of the Prostate Stage I | Adenocarcinoma of the Prostate Stage II | Adenocarcinoma of the Prostate Stage IIIUnited States
-
University of California, San FranciscoCompletedProstate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage III Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7United States
-
National Cancer Institute (NCI)Active, not recruitingCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage II Prostate Adenocarcinoma | Stage I Prostate Adenocarcinoma
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingProstate Adenocarcinoma | Stage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage I Prostate AdenocarcinomaUnited States, Canada, Switzerland
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage III Prostate Adenocarcinoma AJCC v7 | Stage II Prostate Adenocarcinoma AJCC v7 | Stage I Prostate Adenocarcinoma American Joint Committee on Cancer (AJCC) v7United States
-
Andrei IagaruCompletedStage II Prostate Adenocarcinoma | Stage III Prostate Adenocarcinoma | Stage IV Prostate AdenocarcinomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States